Apyx Medical Corporation APYX 深 沪
已收盘 07-02 16:00:00 美东时间
4.30
-0.360
-7.73%
华盛通- 最 高4.85
- 今 开4.70
- 成交量 6.90万股
- 最 低 4.27
- 昨 收 4.66
- 总市值 1.80亿
- 52周最高 5.08
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 1.5902
- 委 比 72.53%
- 总股本 4187.40万
- 历史最高 17.50
- 量 比 0.42
- 振 幅 12.45%
- 历史最低 0.7554
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Apyx Medical Names Vizirgianakis Executive Chairman, Grants RSUs
An update from Apyx Medical ( ($APYX) ) is now available. On June 11, 2026, Apy...
06-18 05:30
Apyx Medical Publishes New Clinical Data In Aesthetic Surgery Journal Open Forum Highlighting Approach To Improving Cellulite And Skin Laxity
In this study, 22 patients received a single treatment session combining these modalities to address both the structural and surface level causes of cellulite and skin laxity. Results showed progressive improvement over
05-21 20:04
Apyx Medical Rides AYON Surge in Latest Earnings
Apyx Medical (($APYX)) has held its Q1 earnings call. Read on for the main high...
05-09 08:46
Apyx Medical shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY2026 sales guidance above estimates.
Apyx Medical shares are trading higher after the company reported better-than-e...
05-08 02:02
Renuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"
Renuvion continues to lead in minimally invasive body contouring as the trusted solution for loose skin. CLEARWATER, Fla., April 1, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APY...
04-01 21:30
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Earnings Scheduled For March 10, 2026
Companies Reporting Before The Bell • Ultralife (NASDAQ:ULBI) is likely to repo...
03-10 19:11
Apyx Medical Q4 revenue beats on Surgical Aesthetics unit strength
Apyx Medical Q4 revenue beats on Surgical Aesthetics unit strength Overview Surgical aesthetics firm's Q4 revenue rose 34.7% yr/yr, beating analyst expectations Adjusted EBITDA for Q4 was positive, beating analyst estimates Company scaling U.S. launch of AYON Body Contouring System amid strong deman
03-10 19:08
Apyx Medical Q4 2025 revenue rises 35% to USD 19.16 million as net loss narrows to USD 1.3 million
Apyx Medical Q4 2025 revenue rises 35% to USD 19.16 million as net loss narrows to USD 1.3 million Apyx Medical reported Q4 FY2025 total revenue of USD 19.16 million, up 35%, driven by a nearly 50% increase in U.S. sales in its Surgical Aesthetics segment. Q4 Surgical Aesthetics revenue was USD 16.7
03-10 19:06
Earnings Breakdown: Apyx Medical Q4
The Q4 earnings report for Apyx Medical (NASDAQ:APYX) was released on Tuesday, ...
03-10 19:02
